GSK-503 for cell activation

GSK-503 is a potent EZH2 inhibitor with potential anticancer activity. Increased activity of the epigenetic modifier EZH2 has been associated with different cancers. In a melanoma mouse model, conditional Ezh2 ablation as much as treatment with the preclinical EZH2 inhibitor GSK503 stabilizes the disease through inhibition of growth and virtually abolishes metastases formation without affecting normal melanocyte biology.

N/A

1346572-63-1

526.67

Biochemicals

N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide

C₃₁H₃₈N₆O₂

Off-white solid

N/A

No

Yes

≥98% by HPLC

DMSO (>5 mg/ml)

-20°C

gel pack

36 months

Protect from air and light

cell

For cells, cell lines and tissues in culture till half confluency.